A Maryland-based biotech company believes it can solve a riddle that has baffled Big Pharma for decades: how to protect against a virus that infects almost every American child.
If mid-stage trial data proves positive, Novavax Inc will be closer than any drug developer to a vaccine for respiratory syncytial virus, or RSV, which affects those most with compromised immune systems - including young infants and the elderly.
An effective vaccine would represent a $1 billion opportunity in the United States and potentially double that worldwide, said Heather Behanna, an analyst at Wedbush Securities.
Help employers find you! Check out all the jobs and post your resume.
